Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer

Bevacizumab (bvz) is currently employed as an anti-angiogenic therapy across several cancer indications. Bvz response heterogeneity has been well documented, with only 10-15% of colorectal cancer (CRC) patients benefitting in general. For other patients, clinical efficacy is limited and side effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuurbier, Linda, Rahman, Arman, Cordes, Martijn, Scheick, Jennifer, Wong, Tse J., Rustenburg, François, Joseph, Jesu Christopher, Dynoodt, Peter, Casey, Rory, Drillenburg, Paul, Gerhards, Michael, Barat, Ana, Klinger, Rut, Fender, Bozena, O’Connor, Darran P., Betge, Johannes, Ebert, Matthias P., Gaiser, Timo, Prehn, Jochen H. M., Griffioen, Arjan W., van Grieken, Nicole C. T., Ylstra, Bauke, Byrne, Annette T., van der Flier, Laurens G., Gallagher, William M., Postel, Ruben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522118/
https://www.ncbi.nlm.nih.gov/pubmed/28487489
http://dx.doi.org/10.18632/oncotarget.17306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522118/
https://www.ncbi.nlm.nih.gov/pubmed/28487489
http://dx.doi.org/10.18632/oncotarget.17306

Ejemplares similares